Clinical Implications of Updated Data from EHA 2024

Opinion
Video

Key opinion leaders evaluate the clinical implications of updated data presented at EHA 2024, interpreting how these findings may influence future treatment strategies in multiple myeloma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • What Is your current strategy and treatment option for maintenance therapy in NDMM for transplant eligible??
      • Please share your thoughts on the updated data from CASSOPEIA. (Moreau P et al. EHA 2024, Abstract S204)
      • How does the data impact frontline treatment for transplant eligible NDMM?
      Recent Videos
      3 experts are featured in this series.
      Second-Line Treatment for Gastric Adenocarcinoma
      3 experts are featured in this series.
      Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches
      3 experts are featured in this series.
      Gastric Adenocarcinoma: Current Treatment Landscape
      3 experts are featured in this series.
      Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW
      3 experts are featured in this series.
      Esophageal/Gastric Adenocarcinoma Standard of Care
      2 experts are featured in this series.
      BESPOKE: Study Design, Efficacy End Points and Methods
      2 experts are featured in this series.
      The Role of ctDNA in CRC
      5 experts in this video
      CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease
      4 experts in this video
      PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
      KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025
      KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025
      Related Content
      Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.

      Talquetamab Elicits Sustained Responses in Pre-Treated R/R Multiple Myeloma

      Roman Fabbricatore
      April 1st 2025
      Article

      Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.

      Daratumumab Continues to Show Activity in Smoldering Multiple Myeloma

      Russ Conroy
      March 23rd 2025
      Article

      Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Final OS analysis data from the OPTIMISMM trial support sequencing a pomalidomide-based regimen after lenalidomide failure in relapsed/refractory myeloma.

      Pomalidomide Combo Sustains Improved Outcomes in Pretreated R/R Myeloma

      Russ Conroy
      March 19th 2025
      Article

      Final OS analysis data from the OPTIMISMM trial support sequencing a pomalidomide-based regimen after lenalidomide failure in relapsed/refractory myeloma.

      Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

      Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

      Tim Cortese
      March 14th 2025
      Article

      Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.